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‘Well woman’ checks are carried out by many clinicians 
including general practitioners, gynaecologists and 
health nurses. The content of these examinations 
has been demonstrated to vary widely, as shown in a 
study by Carney et al.1 In this study, 59 primary care 
physicians reviewed asymptomatic women 55 years of 
age requesting ‘check ups’. Of note, 65% of physicians 
provided a clinical breast examination and another 20% 
did so when prompted. The remaining doctors indicated 
they would perform the examination with the woman’s 
next Pap test. The performance of pelvic examinations 
was not noted in this study. 
Extensive literature review reveals little documentation 
into the frequency of performance of routine pelvic 
examinations in asymptomatic women. Therefore, further 
study into this area of practice is justified, before reviewing 
recommendations regarding the issue. 
The clinical question
The questions to ask are why are we doing pelvic 
examinations in asymptomatic women, and what do women 
believe is the purpose of such examinations? Evidence 
suggests that these intimate examinations may be traumatic 
and stressful to the patient, so we must ensure that we 
have sufficient reason to justify them as reliable screening 
tests.2,3 The examination may also provide false reassurance 
to the patient if they do not have a clear understanding 
of its accuracy. In our clinical experience, patients have 
also commented on the inconsistency with which they 
Case example
Miss L, 26 years of age, attends for her 2 yearly Pap test. She is taking the oral contraceptive pill 
and does not complain of any gynaecological symptoms on routine questioning. As part of the 
consultation you offer her a pelvic examination. She agrees, but asks you why other doctors have 
not offered her this during previous Pap test examinations. She also asks what you are checking for.
BACKGROUND
A routine pelvic examination is often performed as part of a ‘well woman' check, in combination with a Pap test, 
sexually transmitted infection screening, or before commencing the contraceptive pill or hormone therapy. This check is 
also done at the woman’s request, on the understanding that it may screen for ovarian cancer and other pathology.
OBJECTIVE
This article reviews the evidence regarding the use of routine pelvic examination in asymptomatic women as a 
screening test, and if the examination is performed, what information should be imparted to the patient to obtain 
informed consent.
DISCUSSION 
Review of the literature indicates that the use of routine pelvic examination as screening for ovarian malignancy (with or 
without serum CA-125 and ultrasound) cannot be justified due to the low prevalence of the disease and low sensitivity 
and specificity of the examination. Pelvic examinations may be performed at the time of routine Pap tests to aid in 
technical issues with the Pap test itself, but are not recommended for screening purposes. There is no evidence to 
support pelvic examination of asymptomatic women taking hormone therapy or attending for a sexual health check. The 
performance of pelvic examination at the woman’s request must be preceded by thorough gynaecological, medical and 
family history and after obtaining informed consent from the patient.
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are offered these examinations, giving some 
indication regarding differing clinician’s beliefs 
about their value. 
 Many doctors perform the ‘screening’ pelvic 
examination out of ‘habit’ or because they 
were ‘taught’ to do so, rather than for a clear 
clinical indication. The method of performing 
a pelvic examination is relatively standard and 
involves ‘the insertion of one or two examiner 
fingers into the vaginal vault with simultaneous 
palpation of the lower abdomen to characterise 
the size and shape of the uterus and adnexa’.4 
The clinician should be able to palpate the uterus 
between their hands and, in ‘normal’ women, 
should not be able to palpate the ovaries (unless 
the woman is quite thin). An estimate of the 
size, tenderness and uniformity of the uterus 
and ovaries can be made. 
 Pelvic examination in asymptomatic women 
may be offered in the following circumstances:
• to detect ovarian and uterine abnormalities, 
more specifically as screening for ovarian 
carcinoma 
• during a sexually transmitted infection check
• in conjunction with a routine Pap test
• before prescribing the combined oral 
contraceptive pill or hormone therapy.
The literature regarding each of these areas will 
be discussed in turn.
Pelvic examination: literature search
We searched the Cochrane database, Medline, 
Google, and textbooks, using the terms 
‘we l l  woman check ’,  ‘ rou t ine  pe lv i c 
examination’, ‘vaginal examination’, and ‘ovarian 
cancer screening’. Much of the information 
gained was in respect to the topic of ovarian 
cancer screening.
Screening for ovarian cancer and uterine 
abnormalities
A suitable screening test must detect a disease 
that causes significant morbidity and has a high 
prevalence in the population. The disease must 
have a preclinical phase that can be detected and 
is amenable to therapy. The test itself must be 
sensitive, specific, and cost effective and have a 
high positive predictive value.5
 Although ovarian cancer has a relatively low 
prevalence in the community (30–50 women per 
100 000), the anxiety that this illness provokes is 
understandably quite high. The lifetime incidence 
of ovarian cancer is one in 70 women.5 The early 
stages of the disease are asymptomatic but 
more easily treated, while most cases occur late 
causing high mortality. Ovarian cancer has the 
highest mortality of any gynaecological cancer 
with a 5 year survival rate of 75% if cancer 
is confined to the ovaries, and 17% for those 
women presenting with distant metastases. Two-
thirds of women have advanced disease at the 
time of diagnosis.6 The presenting symptoms 
of ovarian cancer are often mild and nonspecific 
such as vague gastrointestinal discomfort, pelvic 
pressure and pelvic pain.5 
 Early detection of ovarian cancer has not 
been shown to lower mortality rates.6 Indirect 
evidence shows that this may not be correct, 
as mortality rates from early stage disease are 
significantly lower than those for late stage 
disease. The National Cancer Institute in America 
has recently embarked on a large study to explore 
this question. With the assumption of 100% 
sensitivity and 30% reduction in 5 year mortality 
with screening, they calculate that annual pelvic 
examinations in women 40 years of age would 
reduce the 5 year mortality from ovarian cancer 
by <0.0001%. Similar calculations using CA-125, 
with or without ultrasound screening, show an 
increase in life expectancy by 1 day for each 
woman screened.6 The UK Collaborative Trial 
of Ovarian Cancer screening, the NIH PLCO 
Screening Trial, and the European Trial of Ovarian 
Cancer Screening are currently also investigating 
the mortality reduction, if any, provided by ovarian 
cancer screening. To date, results of the NIH 
PLCO trial have identified no precursors to ovarian 
cancer in postmenopausal woman. The effect of 
screening in their study population is still unclear 
and requires longer follow up.7
 Various methods of screening for ovarian 
cancer have been suggested, namely pelvic 
examination, transabdominal and vaginal 
ultrasound, and CA-125 testing. It is suggested 
that for ovarian cancer where the prevalence is 50 
per 100 000 women, a test with 100% sensitivity 
and 99% specificity would result in one per 21 
woman positively screened having the disease, 
ie. positive predictive value 4.8%. The sensitivity 
of the proposed methods is currently not high 
enough to warrant their use in screening.5 It 
must also be considered that laparoscopy and/
or laparotomy is the only way to definitively 
diagnose ovarian carcinoma, thus the implications 
of confirming a result is falsely positive involves 
significant morbidity and anxiety.8
 Multiple studies have shown the inaccuracy 
of pelvic examinations in women, even under 
controlled conditions such as anaesthesia. Padilla et 
al9 conducted a study of pelvic examination findings 
in 140 anaesthetised women. Gynaecologists, 
gynaecology residents and medical students 
carried out the examinations. The authors found 
that even in ideal conditions, the overall accuracy 
of the examination was 70.2% for gynaecologists, 
64% for residents and 57.3% for medical students. 
Uterine assessment proved to be more accurate 
than adnexal assessment and was reasonable with 
a sensitivity of 0.64 and specificity of 0.8. Factors 
such as uterine size, abdominal scarring and 
obesity also reduced the assessment accuracy. 
Gladstone10 found that other factors affecting the 
accuracy of bimanual examination include patient 
size, pelvic structure, and patient anxiety level. 
These must be considered also with respect to the 
experience of the practitioner and dimensions of 
the tumour itself if present. 
 The pelvic examination has a low sensitivity 
in detecting adnexal masses. The study by 
Padilla et al showed a sensitivity of 51% and 
positive predictive value of 43.8% for pelvic 
examination, with sensitivity being low even 
for masses greater than 5 cm.9 The positive 
predictive value for left adnexal masses was 
0.5–0.69 and for right adnexal masses 0.26–
0.39, thus not justifying its use as a screening 
test.9 One of the important issues in screening 
is that the disease must be detectable early. 
This is inherently difficult in pelvic examination 
where early ovarian cancers may be small. It is 
estimated that 10 000 pelvic examinations are 
required to detect one ovarian cancer and that 
the lesion is usually advanced.11
 The deep anatomical location of the ovaries 
in the abdomen precludes easy examination and 
reduces examination sensitivity. The majority 
of pelvic masses found are either benign, or 
if malignant, advanced.6 Prevalence of adnexal 
masses in the general population is 0.17–5.9% 
in asymptomatic woman, with the higher 
prevalence being in premenopausal woman. 
It has been calculated that an adnexal mass 
found by pelvic examination would be surgically 
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confirmed 8% of the time, compared to 17% for 
a mass found on ultrasound.6
 Grover and Quinn12 also conducted a study 
to assess the accuracy of pelvic examination 
in healthy women; 2623 healthy asymptomatic 
volunteers, both pre- and post-menopausal 
were assessed with the aim of ovarian cancer 
screening. Findings were further defined with 
ultrasonography and CA-125 levels. Surgical 
intervention was performed if required. Abnormal 
adnexal findings occurred in 1.5% of the 
subjects with a positive predictive value for a 
benign adnexal abnormality of 22%. No ovarian 
malignancies were found in the screening group. 
The authors’ comment that the use of pelvic 
examination as a screening test for ovarian 
carcinoma in a population with a low prevalence 
of ovarian cancer and high prevalence of benign 
adnexal pathology is not warranted.
 Postgraduate experience improved the overall 
accuracy of the pelvic examination, although 
skills appear to plateau after a certain number of 
examinations have been performed.9 This begs 
the question that those who do not routinely 
perform pelvic examinations will have a lower 
sensitivity and specificity for disease detection 
and therefore even less justified at performing 
such examinations as part of screening.9 The 
importance of ongoing education and training 
regarding examination techniques will therefore 
become necessary if pelvic examination is ever 
used as a screening procedure, either alone 
or in conjunction with other modalities. The 
reliance of practitioners on imaging techniques 
in preference to examination may also impact on 
the proficiency with which they perform pelvic 
examinations.9 
 It is worth briefly mentioning other proposed 
screening tools as mentioned in the literature. 
Transvaginal and transabdominal ultrasound lack 
both the sensitivity and sensitivity to justify their 
use in screening. The resulting false positive 
rates may result in diagnostic laparoscopies 
for a relatively low disease yield.6 Ultrasound 
in combination with CA-125 testing somewhat 
increases this, however false positive rates are still 
high.5,10 Serum CA-125 is an antigenic determinant 
that is elevated in 80% of epithelial ovarian 
cancers, however, only 50% of patients with early 
ovarian disease have high levels. Therefore, its use 
in detecting early disease cannot be justified.5,6
What about women at higher risk?
The lifetime risk of ovarian cancer is one in 70, but 
for women with one affected relative, this rate 
rises to 5%. Current literature suggests that the 
previously mentioned screening tests are still not 
justified, even in this high risk population. The risk 
with two affected relatives rises to 7% and again, 
screening in this group has not been justified. It 
is however recommended that specialist review 
be sought in defining hereditary ovarian cancer 
syndromes. For those in this group, lifetime 
risk of ovarian cancer is 40%. Current evidence 
shows no reduction in mortality by screening 
this group, and prophylactic oophorectomy does 
not guarantee that cancer will not develop.5 
If screening such a high risk population is not 
warranted, its benefit to the general population 
must certainly be questioned.
Pelvic examination: sexual health checks
The performance of a pelvic examination as part 
of a sexual health consultation may be justified as 
clinical signs may be elicited that aid in diagnosis. 
It would be unusual however for an asymptomatic 
woman to present with cervical excitation on 
examination without complaining of dyspareunia. 
Schachter13 investigated the use of routine pelvic 
examinations in women presenting for sexual 
health checks. They concluded that delaying 
routine pelvic examinations and Pap tests in this 
group would not adversely affect outcomes. 
Pelvic examinations: Pap tests
The use of pelvic examination when performing 
a Pap test may aid in the actual technique of 
performing the smear. For example, a difficult 
to locate cervix on speculum examination 
may be located after vaginal examination. It is 
important to note that in this instance, the pelvic 
examination is not being used for a ‘screening’ 
purpose. The Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists 
make no mention in their position statement on 
cervical cancer screening of routinely performing 
a pelvic examination with a Pap test.14 They do 
however comment that women attending for care 
understand that complete examination usually 
includes assessment of the breast and pelvis.15 
 It is interesting to note that if pelvic 
examination were recommended as ovarian 
cancer screening, its false positive rate would 
be lower in postmenopausal women due to the 
increased prevalence of the disease in women 
over 60 years of age. Current Pap test screening 
recommendations suggest that cervical screening 
be ceased at 70 years of age in otherwise 
healthy women with no history of previously 
abnormal smears.14,16 If pelvic examinations were 
performed routinely in this group with smears, 
the patient would only have five examinations (ie. 
performed 2 yearly) before ‘screening’ ceased. 
Due to the natural history of ovarian cancer it is 
likely that the number of interval cancers would 
be significant.
Pelvic examination: before hormone therapy 
Pelvic examination before oral contraceptive use is 
common in many countries and is often also done 
annually. Evidence to support such examinations 
is lacking, and false positive results may cause 
inconvenience and anxiety in patients.17 It must 
also be considered that pelvic malignancy 
prevalence rates in this premenopausal population 
are relatively low.
 Although patients taking oral contraceptive 
or hormone therapy are generally ‘well women’, 
it is acknowledged that the effect on breast and 
pelvic disease by the two medication groups may 
be different. Oral contraception use is known to 
reduce the risk of ovarian cancer and fibroids, 
while the role of hormone therapy is unclear. The 
most significant factor contributing to disease 
incidence is the patient’s age rather than the 
medication they are taking. This factor alone does 
not justify the pelvic examination as screening for 
well women.18
Recommendations
• The use of routine pelvic examination as 
screening for ovarian malignancy (with or 
without serum CA-125 and ultrasound) 
cannot be justified due to the low prevalence 
of the disease and low sensitivity and 
specificity of the examination.
• Patients at high risk of ovarian cancer due to 
personal or family history should be referred 
to specialist care for individual consideration 
of screening practices.
• There is no evidence to support the necessity 
for pelvic examination of asymptomatic 
women taking hormone therapy or attending 
for a sexual health check.
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• Pelvic examinations may be performed at the 
time of routine Pap tests to aid in technical 
issues with the smear itself, but are not 
recommended for screening purposes.
• Pelvic examination at a woman’s request must 
be preceded by thorough gynaecological, 
medical and family history and after obtaining 
informed consent from the patient.
Informed consent 
Informed consent should involve the following:
–  discussion with the patient why she is 
requesting the examination
–  explanation that a normal pelvic examination 
does not exclude pathology, particularly 
ovarian cancer
–  the necessity to follow up any abnormal 
examination findings and the morbidity this 
may involve
–  recommendation that the patient seek review if 
she develops gynaecological symptoms, even if 
a recent pelvic examination has been normal.
Conclusion
Although the evidence to date recommends 
against routine pelvic examination as a screening 
procedure for ovarian cancer, it must be 
remembered that there is no other useful and 
reliable method for detection of this indolent 
disease which has great morbidity, mortality, 
financial and emotional cost to individuals and the 
community.8,19 Guidelines for the performance of 
pelvic examination in asymptomatic women are 
varied and often unclear. No Australian guidelines 
could be found. The American Cancer Society 
advises annual pelvic examinations. The Canadian 
Task Force on the Periodic Health Examination 
and the US Preventive Services Taskforce indicate 
the examination is reasonable in conjunction with 
other examinations (eg. Pap test collection).9
 Any request for pelvic examination in an 
asymptomatic woman, particularly with the aim 
of excluding ovarian cancer, must be undertaken 
after thorough history and discussion regarding 
the perceived accuracy of the examination to 
exclude or confirm disease. The frequency of 
performance of pelvic examinations in ‘well 
women’ by doctors and the attitudes surrounding 
such, are the focus of a current qualitative 
research study by this article’s authors. Women 
must also be informed that any abnormalities 
found must be investigated, with the likelihood 
that the pathology is benign and intervention 
would not change disease outcome.
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